Aurobindo may raise funds for the deal with a loan of more than $1 billion.
Aurobindo Pharma is entering the fray to acquire the assets of Teva Pharmaceutical Industries that are being divested by the company in the UK, Ireland and Iceland.
Teva is divesting products over 1.5 billion to get regulatory approval for its $40.5 billion acquisition of Allergan’s generic business in the US and Europe.
Reportedly, Aurobindo may raise funds for the deal with a loan of more than $1 billion. However, the final decision is pending and the company may decide against a bid.